These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 24757085)

  • 1. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors.
    Suh YG; Suh CO; Kim JS; Kim SJ; Pyun HO; Cho J
    Ann Hematol; 2012 Nov; 91(11):1785-93. PubMed ID: 22752147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
    Li X; Sun WJ; Chen SL; Zhong YP; An N; Hu Y; Zhang JJ; Liu XH
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(12):838-41. PubMed ID: 22781459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
    Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
    Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcome in solitary bone plasmacytomata with combined therapy.
    Avilés A; Huerta-Guzmán J; Delgado S; Fernández A; Díaz-Maqueo JC
    Hematol Oncol; 1996 Sep; 14(3):111-7. PubMed ID: 9119355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.
    Knobel D; Zouhair A; Tsang RW; Poortmans P; Belkacémi Y; Bolla M; Oner FD; Landmann C; Castelain B; Ozsahin M;
    BMC Cancer; 2006 May; 6():118. PubMed ID: 16677383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party.
    Kilciksiz S; Celik OK; Pak Y; Demiral AN; Pehlivan M; Orhan O; Tokatli F; Agaoglu F; Zincircioglu B; Atasoy BM; Ozseker N; Yersal O; Niang U; Haydaroglu A;
    Am J Hematol; 2008 Sep; 83(9):702-7. PubMed ID: 18543343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
    Fukushima T; Nakamura T; Miki M; Sakai T; Iwao H; Nakajima A; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Hirose Y; Umehara H
    Anticancer Res; 2010 Sep; 30(9):3791-4. PubMed ID: 20944171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
    Zhong YP; Chen SL
    Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):396-8. PubMed ID: 19615158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years.
    Barzenje DA; Kolstad A; Ghanima W; Holte H
    Hematol Oncol; 2018 Feb; 36(1):217-223. PubMed ID: 28393375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and prognostic factors in solitary plasmacytoma.
    Finsinger P; Grammatico S; Chisini M; Piciocchi A; Foà R; Petrucci MT
    Br J Haematol; 2016 Feb; 172(4):554-60. PubMed ID: 26684545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
    Tan D; Kim K; Kim JS; Eom HS; Teoh G; Ong KH; Goh YT; Durie BG; Chng WJ; Lee JH
    Leuk Res; 2013 Sep; 37(9):1070-6. PubMed ID: 23816344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Solitary plasmacytomas of bone and extramedullary plasmacytomas].
    Yang D; Fan S; Tao H
    Zhonghua Zhong Liu Za Zhi; 1996 Jan; 18(1):41-4. PubMed ID: 8732111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
    Liang Z; Ren H; Cen X; Li Y; Wang L; Ou J; Dong Y; Yin Y; Wang W; Liu W; Wang Q; Qiu Z; Wang M; Xu W; Sun Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):225-30. PubMed ID: 24666489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.
    Ozsahin M; Tsang RW; Poortmans P; Belkacémi Y; Bolla M; Dinçbas FO; Landmann C; Castelain B; Buijsen J; Curschmann J; Kadish SP; Kowalczyk A; Anacak Y; Hammer J; Nguyen TD; Studer G; Cooper R; Sengöz M; Scandolaro L; Zouhair A
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):210-7. PubMed ID: 16229966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.
    Sun WJ; Zhang JJ; An N; Shen M; Huang ZX; Li X
    J Int Med Res; 2016 Dec; 44(6):1462-1473. PubMed ID: 28322099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.